Terms: = Bone cancer AND ASXL1, ENSG00000171456, 171023, Q8IXJ9, MGC71111, MGC117280, KIAA0978 AND Prognosis
50 results:
1. Essential thrombocythemia: 2024 update on diagnosis, risk stratification, and management.
Tefferi A; Vannucchi AM; Barbui T
Am J Hematol; 2024 Apr; 99(4):697-718. PubMed ID: 38269572
[TBL] [Abstract] [Full Text] [Related]
2. Multiple Genomic Alterations, Including a Novel
Sahin Y; Wang YL; Pei J; Mansoor N; Styler M; Testa JR; Nejati R
Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203475
[TBL] [Abstract] [Full Text] [Related]
3. Diagnosis- and prognosis-Related Gene Alterations in
Morishita S; Komatsu N
Int J Mol Sci; 2023 Aug; 24(16):. PubMed ID: 37629188
[No Abstract] [Full Text] [Related]
4. High molecular risk variants, severe thrombocytopenia and large unstained cells count affect the outcome in primary myelofibrosis.
Kanduła Z; Janowski M; Więckowska B; Paczkowska E; Mroczkowska-Bękarciak A; Sobas M; Lewandowski K
J Appl Genet; 2023 Sep; 64(3):479-491. PubMed ID: 37507589
[TBL] [Abstract] [Full Text] [Related]
5. [Clinical Analysis of Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm].
Cheng P; Wang QX; Wang LL; Guan J; Zhou Y; Zhang T; Su F; Chen LQ; Cao Y; Cheng H; Zou L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Jun; 31(3):896-901. PubMed ID: 37356957
[TBL] [Abstract] [Full Text] [Related]
6. Co-occurring mutations in asxl1, SRSF2, and SETBP1 define a subset of myelodysplastic/ myeloproliferative neoplasm with neutrophilia.
Jain T; Ware AD; Dalton WB; Pasca S; Tsai HL; Gocke CD; Gondek LP; Xian RR; Borowitz MJ; Levis MJ
Leuk Res; 2023 Aug; 131():107345. PubMed ID: 37354804
[TBL] [Abstract] [Full Text] [Related]
7. Hypoplastic form of myelodysplastic neoplasm.
Votavová H; Lenertová Z; Votava T; Beličková M
Klin Onkol; 2023; 36(3):206-214. PubMed ID: 37353349
[TBL] [Abstract] [Full Text] [Related]
8. Clonal Hematopoiesis of Indeterminate Potential: Current Understanding and Future Directions.
Singh I; Singh A
Curr Oncol Rep; 2023 Jun; 25(6):539-547. PubMed ID: 36928826
[TBL] [Abstract] [Full Text] [Related]
9. Hitting the brakes on accelerated and blast-phase myeloproliferative neoplasms: current and emerging concepts.
Bewersdorf JP; Rampal RK
Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):218-224. PubMed ID: 36485103
[TBL] [Abstract] [Full Text] [Related]
10. JAK2V617F variant allele frequency, non-driver mutations, single-nucleotide variants and polycythemia vera outcome.
Kanduła Z; Janowski M; Więckowska B; Paczkowska E; Lewandowski K
J Cancer Res Clin Oncol; 2023 Jul; 149(8):4789-4803. PubMed ID: 36242602
[TBL] [Abstract] [Full Text] [Related]
11. Allogeneic hematopoietic cell transplantation can overcome the adverse prognosis indicated by secondary-type mutations in de novo acute myeloid leukemia.
Song GY; Kim T; Ahn SY; Jung SH; Kim M; Yang DH; Lee JJ; Choi SH; Kim MY; Jung CW; Jang JH; Kim HJ; Moon JH; Sohn SK; Won JH; Park SK; Kim SH; Zhang Z; Ahn JS; Kim HJ; Kim DDH
Bone Marrow Transplant; 2022 Dec; 57(12):1810-1819. PubMed ID: 36151367
[TBL] [Abstract] [Full Text] [Related]
12. Evaluating the frequency, prognosis and survival of RUNX1 and asxl1 mutations in patients with acute myeloid leukaemia in northeastern Iran.
Parsa-Kondelaji M; Ayatollahi H; Rostami M; Sheikhi M; Barzegar F; Afzalaghaee M; Moradi E; Sadeghian MH; Momtazi-Borojeni AA
J Cell Mol Med; 2022 Jul; 26(13):3797-3801. PubMed ID: 35692075
[TBL] [Abstract] [Full Text] [Related]
13. Myelofibrosis: Genetic Characteristics and the Emerging Therapeutic Landscape.
Tefferi A; Gangat N; Pardanani A; Crispino JD
Cancer Res; 2022 Mar; 82(5):749-763. PubMed ID: 34911786
[TBL] [Abstract] [Full Text] [Related]
14. The CADM1 tumor suppressor gene is a major candidate gene in MDS with deletion of the long arm of chromosome 11.
Lafage-Pochitaloff M; Gerby B; Baccini V; Largeaud L; Fregona V; Prade N; Juvin PY; Jamrog L; Bories P; Hébrard S; Lagarde S; Mansat-De Mas V; Dovey OM; Yusa K; Vassiliou GS; Jansen JH; Tekath T; Rombaut D; Ameye G; Barin C; Bidet A; Boudjarane J; Collonge-Rame MA; Gervais C; Ittel A; Lefebvre C; Luquet I; Michaux L; Nadal N; Poirel HA; Radford-Weiss I; Ribourtout B; Richebourg S; Struski S; Terré C; Tigaud I; Penther D; Eclache V; Fontenay M; Broccardo C; Delabesse E
Blood Adv; 2022 Jan; 6(2):386-398. PubMed ID: 34638130
[TBL] [Abstract] [Full Text] [Related]
15. [Clinical impact of gene mutations on myeloproliferative neoplasms in Japan].
Morishita S
Rinsho Ketsueki; 2021; 62(8):1060-1069. PubMed ID: 34497192
[TBL] [Abstract] [Full Text] [Related]
16. Clinical and histopathological features of myeloid neoplasms with concurrent Janus kinase 2 (JAK2) V617F and KIT proto-oncogene, receptor tyrosine kinase (KIT) D816V mutations.
Naumann N; Lübke J; Shomali W; Reiter L; Horny HP; Jawhar M; Dangelo V; Fabarius A; Metzgeroth G; Kreil S; Sotlar K; Oni C; Harrison C; Hofmann WK; Cross NCP; Valent P; Radia D; Gotlib J; Reiter A; Schwaab J
Br J Haematol; 2021 Jul; 194(2):344-354. PubMed ID: 34060083
[TBL] [Abstract] [Full Text] [Related]
17. Co-occurrence of
Jin H; Zhu Y; Hong M; Wu Y; Qiu H; Wang R; Jin H; Sun Q; Fu J; Li J; Qian S; Qiao C
Leuk Lymphoma; 2021 Oct; 62(10):2428-2437. PubMed ID: 34024223
[TBL] [Abstract] [Full Text] [Related]
18. Clinical implications of sequential MRD monitoring by NGS at 2 time points after chemotherapy in patients with AML.
Tsai CH; Tang JL; Tien FM; Kuo YY; Wu DC; Lin CC; Tseng MH; Peng YL; Hou MF; Chuang YK; Liu MC; Liu CW; Yao M; Lin LI; Chou WC; Chen CY; Hou HA; Tien HF
Blood Adv; 2021 May; 5(10):2456-2466. PubMed ID: 33999144
[TBL] [Abstract] [Full Text] [Related]
19. Accelerated Phase of Myeloproliferative Neoplasms.
Shahin OA; Chifotides HT; Bose P; Masarova L; Verstovsek S
Acta Haematol; 2021; 144(5):484-499. PubMed ID: 33882481
[TBL] [Abstract] [Full Text] [Related]
20. Systemic mastocytosis in adults: 2021 Update on diagnosis, risk stratification and management.
Pardanani A
Am J Hematol; 2021 Apr; 96(4):508-525. PubMed ID: 33524167
[TBL] [Abstract] [Full Text] [Related]
[Next]
